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Abstract 
Human tau phosphorylation has been studied in transfected COS-I cells. Treatment with okadaic acid alters the electrophoretic 
mobility of human tau protein transiently expressed in transfected cells, due to an increase in the level of phosphorylation. Treatment with 
okadaic acid also results in an increased phosphorylation of Alzheimer's disease-type phosphoepitopes. Tau phosphorylation within 
COS-1 cells is partially inhibited by in vivo treatment with DRB, a protein kinase inhibitor. Double treatment of transfected cells with 
okadaic acid and DRB reveals that phosphorylation f tau protein at the AT8 epitope is achieved by a DRB-resistant protein kinase which 
is different from that responsible for tau phosphorylation atthe SMI-31 epitope, which appears to be sensitive to DRB. 
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1. Introduction 
Tau protein is a brain microtubule associated protein 
(MAP) that facilitates tubulin polymerisation i vitro [1,2] 
and stabilises microtubule assembly in vivo [3-5]. Tau 
protein is of interest because it has been shown to be the 
main component of paired helical filaments (PHF), aber- 
rant structures that are present in the brain of Alzheimer's 
disease (AD) patients [6-15]. In AD, tau protein no longer 
binds to microtubules [11] in some neurons and it has a 
higher phosphate content han tau isolated from unaffected 
controls [6,12,16,17]. Thus, hyperphosphorylation of tau 
has been correlated with its presence in PHF [ 18]. 
Tau phosphorylation has been analysed by using differ- 
ent monoclonal antibodies that recognise ither phospho- 
rylated or unphosphorylated forms of the protein. Exam- 
ples of those antibodies are SMI-31 (recognises erines 
396 and 404, in phosphorylated form) [19], AT8 (recog- 
nises phosphoserine 202) [20] or tau-1 (recognises erine 
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202 in unmodified form) [21-23]. Antibodies that recog- 
nise phosphoserines react with PHF tau but not control tau. 
This has therefore been termed Alzheimer-like phospho- 
rylation which could be the consequence of the action of 
active protein kinases and/or inactive protein phospha- 
tases [24]. Several kinases can modify tau in vitro at the 
previously indicated serines (for a review see Ref. [25]), 
but little is known about those acting in vivo. 
In order to analyse the in vivo tau phosphorylation, 
transfections studies have been carried out. Previous stud- 
ies [26-28] have indicated the suitability of this procedure 
since there is no interference with endogenous proteins due 
to the neuronal origin of tau protein, and because tau 
expressed in these transfected cells is indeed phospho- 
rylated [26,29,30] in an Alzheimer-like state [31,32]. 
We and others have recently shown that tau protein 
transiently expressed in COS cells is phosphorylated in
some of the epitopes also present in AD-tau [28,31]. In this 
work we have studied the Alzheimer-like phosphorylation 
in tau-transfected COS-1 cells looking at the conditions in 
which tau is phosphorylated, the possible protein kinases 
involved in that phosphorylation a d the functional conse- 
quences of that modification. 
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2. Materials and methods 
2.1. Materials 
The protein kinase inhibitor 5,6-dichloro-l-/3-D- 
ribofuranosyl-benzimidazole (DRB) was purchased from 
Sigma. The protein phosphatase inhibitor okadaic acid 
(OkA) was purchased from LC Laboratories (Woburn, 
MA). Tau monocional antibodies 7.51 ([33], a kind gift of 
Dr. Wischik, MRC, Cambridge, UK); Tau-I ([34], a kind 
gift of Dr. Binder, MGC, IL); SMI-31 and SMI-35 (Stern- 
berger Monoclonals, MD) and AT8 (a kind gift of Dr. 
Dello, Innogenetics, Belgium) were used. Antibodies pe- 
cific against different protein kinases, including GSK3/3 
(Transduction Laboratories, Lexington, KY), cdk4 (Santa 
Cruz Biotechnology, CA), casein kinase II, cdc2 and MAP 
kinase (UBI, Lake Placid, NY), were also used. Alkaline 
phosphatase was purchased from Boehringer Mannheim 
and assayed as previously indicated [35]. Synthetic oligo- 
nucleotides were from Isogen Bioscience (Amsterdam). 
2.2. Cell culture and transfection studies 
African green monkey kidney fibroblast (COS-l) cells 
[36] were grown in Dulbecco's-modified Eagle's medium 
supplemented with 5% fetal calf serum. Cells were trans- 
fected by using lipofectin (Gibco-BRL) essentially as de- 
scribed by Montejo de Garcini et al. [37]. Unless stated, 
treatment of cells with OkA and DRB was performed in 
serum-free medium at 1 #M for 2 h and 0.1 mM for 4 h, 
respectively. OkA and/or DRB were added to the cells at 
around 60 h post-transfection. 
2.3. Protein preparation 
Microtubule protein was isolated as described by She- 
lanski et al. [38]. Taxol-stabilised microtubules were puri- 
fied by the method of Vallee [39]. Brain tubulin depleted 
of MAPs was isolated from bovine brain by phospho- 
cellulose chromatography [1]. Cytoplasmic extracts of 
transfected cells were obtained by several freezing-thawing 
cycles in buffer A (100 mM Pipes, pH 6.5; 0.5 mM 
MgCI2; 2 mM EGTA) containing protease inhibitors (1 
mM PMSF; 10 /zg/ml aprotinin; 10 /.tg/ml leupeptin; l0 
/_tg/ml pepstatin). After incubation in a boiling water bath 
for 5 min, the heat-stable supernatant was stored frozen 
until use. 
2.4. Western blot analysis 
Protein characterisation by gel electrophoresis and 
Western blot [40] was carried out using tau-specific mono- 
clonal antibodies (see above) and goat anti-mouse peroxi- 
dase conjugated antibody (Dako). The peroxidase reaction 
was developed using 4-chloro-l-naftol and hydrogen per- 
oxide as substrates. 
2.5. Assay for the interaction of tau protein with micro- 
tubules 
To calculate the dissociation constant (K d) for the 
interaction of tau with microtubules, constant amounts of 
tau protein from transfected COS-I cells were mixed with 
increasing amounts of taxol-polymerised microtubules fol- 
lowing the method escribed by Butner and Kirschner [41]. 
Kj corresponds to the concentration of tubulin at which 
50% of tau protein is associated with the assembled poly- 
mers. 
2.6. Expression and purification of recombinant tau .from 
E. coli 
Human tau cDNA clone htau37 was kindly supplied by 
M. Goedert (MRC, Cambridge, UK). Recombinant tau 
proteins were expressed in E. coli and purified as de- 
scribed elsewhere [28]. 
2.7. Construction of expression plasmids 
Construction of plasmids pSGT30, pSGT40, pSGT32, 
pSGT42, pSGT3RC and pSGT4RC for transient expres- 
sion in COS-I cells has been already described [28,37]. To 
obtain plasmids pRKT32N and pRKT3RC for inducible 
expression in E. coli, mutagenesis was carried out using 
the polymerase chain reaction (PCR). Oligonucleotides A5 
(GCGGATCCATATGCCAGAC CTG) and A6 (GCG- 
GATCCATATGGCTGAGCCC), which include the initia- 
tion codon as well as Bam HI and Nde I sites for a proper 
cloning into the vector, were used as 5' primers. Oligo- 
nucleotides A7 (GCGAATTCTTACTCGCGGAAGG) and 
A8 (GCGAATTCTCACAAACCCTGCTTGG), which in- 
clude a stop codon and an Eco RI site downstream, were 
used as 3' primers. The fragment generated by PCR am- 
plification on pSGT32N using primers A6 and A7 (1058 
bp) was digested with Nde I and Eco RI and ligated into 
Nde I- and EcoRI-digested pRK172 [42], thus obtaining 
pRKT32N. In a similar way, the fragment generated by 
PCR amplifications on pSGT3RC or pSGT4RC using 
primers A5 and A8 (503 bp) were digested with NdeI and 
EcoRI and ligated into pRK172 also digested with Ndel 
and EcoRI to obtain pRKT3RC or pRKT4RC, respec- 
tively. All plasmids were analysed by restriction analysis 
to test for proper orientation and correct size of the inserts. 
Finally, when cDNAs obtained by PCR amplification were 
tested by sequencing, no changes regarding the template 
sequences were observed. An schematic diagram of all 
cDNA constructs used throughout this study is shown in 
Fig. 1. 
2.8. Chromatography 
Fractionation of tau protein kinase activities present in 
COS-1 cells was achieved by fast performance liquid 
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Fig. I. Human tau cDNA constructs used throughout this study. Their 
construction and expression of these constructs are described in Section 2. 
Extra exons at the amino region and the tubulin binding domain (TBD) 
are shaded. 
chromatography (FPLC) following basically the method 
described by Ahn et al. [43]. COS-1 cells were ho- 
mogenised in a buffer containing 50 mM glycerophos- 
phate, pH 7.3; 1 mM EGTA; 0.1 mM Na3VO4; 1 mM 
DTT; 1 p,g/ml leupeptin and 10 /~g/ml aprotinin. COS-1 
cell homogenate was fractionated through a Mono Q 
HR5/5 column for anion exchange by using the FPLC 
system (Pharmacia-LKB iotechnology). After loading the 
sample and a brief wash, protein was eluted with a 0-0.4 
M NaCI gradient in the same buffer at 0.5 ml/min. 1-ml 
fractions were collected, the optical density at 280 nm was 
determined and fractions were used to test for protein 
kinase activity using bacterially expressed tau protein as 
substrate. 
2.9. Protein kinase assays 
30 pA from the fractions eluted from the FPLC column 
were assayed for protein kinase activity on tau protein in a 
buffer containing 20 mM Tris-HCl, pH 7.5; 5 mM MgC12; 
1 p,M okadaic acid; 1 /~g/ml leupeptin; 10 /~g/ml 
aprotinin; 2 /xg tau protein from E. coli; 50 p,M ATP and 
10 #Ci [y-32P]ATP. Reactions were performed at 37°C 
for 2 h and stopped by adding electrophoresis loading 
buffer and boiling for 3 min. Phosphorylation was anal- 
ysed by autoradiography after running the phosphorylated 
samples on a 10% acrylamide gel electrophoresis. Those 
fractions containing protein kinase activities able to phos- 
phowlate tau protein were then assayed in the same buffer, 
with increased cold ATP at 1 mM and incubated for 6 h. 
Phosphorylation of tau protein was followed by Western 
blot analysis using monoclonal antibodies specifically 
recognising phosphorylated pitopes. For in vitro inhibi- 
tion experiments, DRB was used at 50 /~M. 
3. Results 
3.1. Tau phosphoo, lation in transfected COS-1 cells 
3.1.1. Treatment with okadaic acid ahers the elec- 
trophoretic mobilio' of tau protein 
Expression of the different human tau isoforms in COS- 1 
cells results in the appearance of more than one elec- 
trophoretic species [28]. Since it has been suggested that 
the presence of more than one isoform could be the 
consequence of phosphorylation events [28-30], trans- 
fected cells were incubated with okadaic acid (OkA) to 
further analyse that modification. 
Okadaic acid, a polyether fatty acid isolated from a 
marine sponge, is a very potent specific inhibitor of protein 
phosphatase I (PPI) and protein phosphatase 2A (PP2A) 
(reviewed in Ref. [44]). As OkA is hydrophobic, it can 
enter cells, and is therefore of use for studying tau 
phosphorylation i  different systems uch as human brain 
slices [45], LA-N-5 [46] and SKNSH-SY 5Y [47] neurob- 
lastoma cells and neuronal primary cultures [48]. 
COS-I cells were transfected with plasmids pSGT32 or 
pSGT3RC (see Fig. 1) and after treatment with the phos- 
phatase inhibitor a mobility shift was observed for T32, 
appearing as a major band with a lower electrophoretic 
mobility. In the case of T3RC, all tau protein appears to 
migrate as a band with slower electrophoretic mobility 
(data not shown). Further in vitro treatment with alkaline 
phosphatase of those tau isoforms expressed in COS-1 
cells resulted in an increase in electrophoretic mobility 
(not shown), strongly suggesting that the electrophoretic 
mobility shift induced by okadaic acid is indeed due to an 
increase in the level of tau phosphorylation. 
3.1.2. Okadaic acid induces an increase in the AD-O,pe 
phosphorylation 
To test if the observed increase in the level of tau 
phosphorylation occurs in those sites reported for the 
Alzheimer-like state, tau isolated from transfected COS-1 
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Fig. 2. Appearance of AD-type phosphorylated pitopes after OkA treatment. COS-I cells were transfected with pSGT32 and treated with increasing 
amounts of okadaic acid. Cell extracts were run on a 10-20% acrylamide lectrophoresis gel, electroblotted and developed with monoclonal antibodies 
7.51, tau-I, AT8, SMI-31 and SMI-35. 
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cells and treated with OkA was tested for their reaction 
with tau-specific monoclonal antibodies tau-l, AT8, SMI- 
31 and SMI-35. Higher concentrations of OkA may be 
needed in the medium of cultured cells because the intra- 
cellular concentrations of PP1 and PP2A often lie in the 
range of 0.1-1.0 /xM [44,49]. For this reason we wanted 
to study the effect of increasing amounts of OkA on tau 
phosphorylation i  transfected COS- 1 cells. 
Fig. 2 indicates that OkA induces an increase in the 
slow-electrophoretic migrating form, detected with an anti- 
body, 7.51, which recognises tau protein [33] indepen- 
dently of its phosphorylation state. In addition, treatment 
of cells with increasing concentrations of OkA, results in a 
decrease in the interaction of tau protein with the antibody 
tau-1 (which recognises an epitope containing serine 202 
in a dephosphorylated form), whereas the reaction with 
antibody AT8 (which recognises erine 202 when is modi- 
fied) or with antibody SMI-31 (which recognises an epi- 
tope including phosphoserines 396 and 404) increase in 
those conditions. 
As expected, appearance of AD-type phosphorylated 
epitopes is dose-dependent, with AT8 and SMI-31 reac- 
tions appearing around 0.5 /zM OkA. Reaction with an- 
other monoclonal, SMI-35 (which recognises undefined 
phosphorylated pitopes on tau protein), was also observed 
to increase upon OkA treatment of the transfected cells 
(data not shown). Also as expected, reaction with these 
antibodies was abolished by in vitro treatment with alka- 
line phosphatase, with the exception of tau-1, which was 
increased. 
3.1.3. Tau phosphorylation is partially inhibited by treat- 
ment of cells with DRB 
As a complement to the previous experiments using 
OkA, we interfered with the phosphorylation process by 
inhibiting protein kinases involved in the observed tau 
phosphorylation. A ribofuranosyl-benzimidazole derivative 
was used as a possible protein kinase inhibitor. 5,6-di- 
chloro-l-/3-ribofuranosyl-benzimidazole (DRB), which has 
the ability to pass through the cell membrane [52], is a 
powerful inhibitor of casein kinase-1 (CKl) and -2 (CK2) 
[50,511. 
Fig. 3 shows the results obtained for COS-1 cells 
transfected with different human tau isoforms and frag- 
ments and then treated with DRB. Treatment with DRB 
induces a change in the relative intensity of the two bands 
corresponding to tau protein, increasing the amount of tau 
protein with a higher mobility, both in the whole tau 
isoforms and the N-terminal truncated tau fragments. An 
increase in the amount of DRB (up to 1 mM) or in the 
time of treatment (up to 8 h) does not further affect tau 
mobility. This result strongly suggests that DRB is only 
partially able to inhibit tau phosphorylation within COS-1 
cells, as determined by the induced electrophoretic mobil- 
ity shift. 
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Fig. 3. Treatment of transfected COS-I ceils with DRB. COS-I ceils were 
transfected with either pSGT30, pSGT40, pSGT32, pSGT42, pSGT3RC 
or pSGT4RC and then treated (+)  or untreated ( - )  with DRB as 
indicated in Section 2. Cell extracts were run on a 10-20% acrylamide 
electrophoresis gel, electroblotted and developed with monoclonal anti- 
body 7.51. 
3.1.4. Double treatment of cells with okadaic acid and 
DRB 
The phosphorylation state of a protein within the cell is 
the result of a balance between the protein kinase and 
protein phosphatase activities acting on it. As shown above, 
DRB can partially inhibit tau phosphorylation within trans- 
fected COS-1 cells. In order to know how DRB affects the 
AD-type tau phosphorylation, double treatment of trans- 
fected cells with OkA and DRB was performed and tau 
phosphorylation was studied using AT8 and SMI-31 anti- 
bodies. 
The reactivity of tau protein expressed in COS-1 cells 
with monoclonal antibodies AT8, SMI-31 and SMI-35 in 
the absence of OkA treatment is very weak, if any, as 
previously reported [28,31]. The observed reactivity after 
OkA treatment of transfected cells can be reversed by the 
presence of DRB, particularly in the case of SMI-31 
antibody, when reactivity almost disappears (data not 
shown). This difference in sensitivity to DRB treatment 
result seems to suggest that the protein kinase activity 
responsible for phosphorylation atboth sites is different. 
3.2. Interaction of phosphorylated tau with microtubules 
To analyse the effect of OkA-induced tau hyperphos- 
phorylation on its ability to bind microtubules, an assay 
was carried out to measure the interaction of tau with 
taxol-stabilised microtubules. The interaction of COS-1 
expressed tau, after treatment with OkA, was measured by 
taking a constant amount of protein from COS-1 cell 
extracts transfected with tau (T32) and mixed with increas- 
ing amounts of taxol-stabilised microtubules from bovine 
brain tubulin, following the procedure of Butner and 
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Kirschner [41]. We took into account hat the microtubule 
concentration, in which half of the tau protein was associ- 
ated to the assembled polymer, corresponds to the dissocia- 
tion constant (K  d) for the interaction of tau with micro- 
tubules. 
A K d of 0.7 _+ 0.2 /xM was determined for tau protein 
obtained from COS- 1 cells in the absence of OkA, whereas 
a K d of 0.9 + 0.3 /xM was found for tau from OkA-treated 
COS-1 cells. This result indicates that, in the conditions in 
which serines 202, 396 and 404 are modified, no great 
differences in the interaction with microtubules, with re- 
spect to tau with unmodified serines, can be observed 
3.3. Tau protein kinase activities in COS-I cells 
3.3.1. FPLC fractionation of tau protein kinase activities 
from COS-1 cells 
In order to identify the protein kinases present in COS-1 
cells which are able to phosphorylate tau protein, the 
procedure of Ahn et al. [43] was followed. A COS-1 cell 
homogenate was loaded on a mono Q fast protein liquid 
chromatography (FPLC) column, eluted with a gradient of 
NaC1 and the resulting fractions were tested for protein 
kinase activity using recombinant tau protein as substrate. 
Fig. 4A shows the fractionation profile determined by 
optical density at 280 nm. 
The different fractions obtained by FPLC were assayed 
for protein kinase activity in the presence of recombinant 
tau protein or its absence (as a control measuring endoge- 
nous phosphorylation of the column fractions). Fig. 4B 
shows those fractions in which a protein kinase activity 
able to phosphorylate au protein. Since tau protein cannot 
be quantitatively precipitated by the addition of cold tri- 
chloroacetic acid, phosphorylation level was determined by 
gel electrophoresis followed by counting radioactivity as- 
sociated with tau protein bands. 
3.3.2. Identification of protein kinase activities.from COS-1 
cells 
To identify which protein kinase activity is present in 
each FPLC column fraction, a dot blot analysis using 
antibodies specifically recognising different protein ki- 
nases was carried out, including cdc2, cdk4, MAP kinase 
(ERKI and ERK2), GSK 3 (j3 isoform) and CK2. As 
shown in Fig. 4C, GSK3/3 is present in the fraction not 
retained in the column (F, flowthrough), whereas cdc2 
appears in fraction 12, MAP kinase seems to be present 
mainly in fraction 16 and and CK2 is present in fraction 29 
(not shown in the figure). Less clear is the position of cdk4 
because the reaction was very weak. 
The presence of these protein kinases in the indicated 
fractions was confirmed by running a sample of each 
column fraction on a electrophoresis gel and performing a
Western blot analysis with the specific antibodies as shown 
in Fig. 5A. It must be noted that the different protein 
kinases-enriched fractions after chromatography are obvi- 
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Fig. 4. FPLC fractionation of tau protein kinase activities from COS-I 
cells. A COS-1 cell homogenate was loaded on a mono-Q FPLC column 
and eluted with a NaCI gradient as described in Section 2. A. Fractiona- 
tion profile determined by optical density at 280 nm. B. In vitro tau 
phosphorylation by protein kinase activities present in mono-Q column 
fractions. C. Dot blot analysis of column fractions using specific antibod- 
ies against different protein kinases. 
ously not homogenous and the presence of other protein 
kinases for which we have not tested cannot be ruled out. 
A further analysis was carried out to test whether the 
modification by any of these protein kinases would in turn 
alter the electrophoretic mobility of tau protein. As shown 
in Fig. 5B, an electrophoretic mobility shift is more evi- 
dent when tau protein is modified by the protein kinase 
activity present in fraction F than the one present in 
fraction 16. Since a possibility still remains that GSK3/3 
may not be the only protein kinase activity present in 
fraction F, a further purification step was followed by 
performing an heparin-sepharose chromatography [53]. 
GSK3 (/3 isoform) purified after this step was also shown 
to modify tau protein in such a way that its electrophoretic 
mobility decreased (Moreno et al., unpubl, results). 
In vitro tau phosphorylation experiments in the presence 
of this inhibitor were carried out in order to identify the 
protein kinase activities from COS-I cells which are inhib- 
ited by in vivo DRB treatment. Our preliminary results 
indicate that the protein kinase activities present in both 
MAP kinase- and GSK 3-enriched fractions are, at least 
partially inhibited by DRB when assayed in vitro on 
recombinant tau protein (data not shown). 
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3.3.3. In vitro phosphorylation of AD-type epitopes by 
protein kinase activities from COS-1 cells 
We were also interested in whether some of these 
protein kinase activities were able to modify tau protein at 
the epitopes recognised by monoclonal ntibodies AT8 and 
SMI-31. As shown in Fig. 5C and D, fraction 16 (MAP 
kinase-enriched fraction)-kinase modifies those serines 
present in the epitopes recognised by both antibodies, 
whereas fraction F (GSK 3/3-enriched fraction)-kinase 
mainly modifies the region recognised by antibody SMI-31. 
To complement the previous analyses, we tested for the 
ability of the protein kinase activities present in the differ- 
ent mono-Q column fractions to modify the amino-termi- 
nal region, the carboxy-terminal region of tau protein, or 
both. To do this, tau fragments T32N and T3RC expressed 
in E. coli were used as substrates. We have used either 
fractions with the maximum activity or the adjacent ones. 
In the case of Fig. 6 we have used fraction 14, which 
according to Fig. 4C have both cdc2 and MAP kinase 
A 
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Fig. 5. Identification of protein kinase activities from COS-1 cells. A, 
Western blot of column fractions F, 12, 16 and 29 using specific 
antibodies against different protein kinases. B, C and D. Western blots of 
the in vitro tau phosphorylation by protein kinase activities present in the 
mono-Q column fractions using tan-specific monoclonal antibodies 7.51 
(B), AT8 (C) or SMI-31 (D). 
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Fig. 6. In vitro tau phosphorylation by protein kinase activities from 
COS-I cells. Column fractions F, 3, 10, 14 and 16 were used to 
phosphorylate in vitro tau fragments T32N (N) and T3RC (C) in the 
presence of [ 32 P]ATP. A negative control ( - )  without adding tau protein 
is also shown. After reaction, samples were run on a electrophoresis gel 
and exposed to X-ray film. The autoradiograph is shown. 
activities, but not cdk4, which can be weakly detected on 
fraction 12. We use then fraction 10 trying to use a more 
cdc2 kinase-enriched fraction, with no presence of the 
previous two activities. 
As shown in Fig. 6, all fractions tested were able to 
modify both tau fragments, with a significant mobility shift 
observed for T3RC, specially in the case of fraction F. 
These data also show that both bands of the doublet are 
phosphorylated, suggesting that phosphorylation at certain 
residues is required for inducing a mobility shift, whereas 
phosphorylation at different residues than those does in- 
duce it. 
4. Discussion 
The phosphorylation state of a protein within a cell 
depends on the relative activities of protein kinases and 
protein phosphatases acting on it. We have studied tau 
phosphorylation within transfected COS-1 cells by in vivo 
interference with these phosphorylation/dephosphoryla- 
tion processes. Tau phosphorylation status can be followed 
by changes in the electrophoretic mobility of the protein 
and also by using monoclonal antibodies specifically 
recognising phospho-epitopes. 
Tau phosphorylation has been studied in a number of 
different mammalian cell lines, including CHO [32], 3T3 
[30] and COS [28,31] cells. Transfected tau in CHO and 
3T3 cells displays some AD-type phosphoepitopes, as
indicated by its reactivity with some monoclonal antibod- 
ies such as AT8 and SMI-31. However, when expressed in
COS cells, a very weak reactivity with these antibodies can 
be detected [28,31]. 
We have presented here evidence that, after treatment 
of transfected cells with OkA, tau protein expressed in 
COS-1 cells acquires some of the features of tau from 
PHF, as determined by its slower electrophoretic mobility, 
hyperphosphorylation and the presence of AD-type phos- 
phorylated epitopes. 
The observed ifferences in the phosphorylation state of 
tau protein between the different mammalian cells lines are 
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likely to be due to different tau protein kinase/phos- 
phatase activity ratios in those cell lines. An explanation 
could be that the apparent higher turnover ate of phos- 
phate observed in COS cells (as suggested by the low 
reactivity with antibodies AT8 and SMI-31 in the absence 
of OkA treatment) may be due to a higher phosphatase 
activity in these cells. 
However, as mentioned, tau protein from transfected 
COS-1 cells appears to be in both unphosphorylated or 
phosphorylated forms, both states being differentiated by 
changes in the electrophoretic mobility of the protein. The 
constitutive presence of phosphoisoforms of tau could be 
due to the absence of a phosphatase activity, such phos- 
phatase activity could be PP2B, that should have a very 
low level in COS-1 cells. However, preliminary experi- 
ments suggest hat the constitutive tau phosphoisoforms 
cannot be dephosphorylated in vitro by that phosphatase. 
Another possibility could be that the appearance of 
phosphorylated tau is the result of a low level of PP2A 
activity that could actively work on phosphorylated tau 
[54,55]. This phosphatase could be downregulated in trans- 
fected COS-I cells, since the enzymatic activity is cell 
cycle regulated [56] and transfected cells are out of cell 
cycle. 
OkA is a potent inhibitor of both PPl and PP2A. Under 
normal in vitro assay conditions, PP2A is completely 
inhibited by I nM OkA, while PPl is unaffected at this 
concentration, its ICs0 being 10-15 nM [40]. However, the 
use of this inhibitor to discriminate between the effects of 
two target enzymes is not as powerful in living cells as it 
is in cell extracts. Inhibition constants in cells may be 
influenced by a number of factors, including intracellular 
concentrations of either competing target enzymes or ef- 
fectors that may compete at the inhibitor binding site, cell 
permeability, half-life of compounds, etc. Our results show 
that we cannot distinguish between PP1 vs. PP2A effects 
in living cells by using OkA. However, based on previous 
in vitro experiments, a possible effect of PPI on the 
dephosphorylation f certain residues of tau protein, such 
as those recognised by SMI-31 antibody, could be ex- 
cluded [55,60]. 
In order to characterise the protein kinase activities 
involved in the modification of tau protein in COS-1 cells, 
we tried to interfere with the phosphorylation process by 
using DRB as a protein kinase inhibitor. Our results 
strongly suggest hat treatment of transfected cells with 
DRB partially inhibits tau phosphorylation, This inhibitor 
has been described as specific for CK1 and CK2 [51,52] 
and also for an undefined protein kinase activity from 
HeLa cells which is able to modify the synthetic peptide 
K(YSPTSPS) 4 [57]. Sequence of this peptide seems to be 
suitable for modification by proline-directed protein ki- 
nases. We have tried to identify the different protein kinase 
activities present in COS-I cells upon fractionation by 
FPLC and to assay their ability to phosphorylate tau in 
vitro. 
We have been able to identify MAP kinase-, GSK 3, 
cdc 2-, cdk4- and CK2-enriched fractions from a COS-l 
cell extract. As expected, protein kinase activities present 
in these fractions were able to phosphorylate au protein in 
vitro both at the N- and C-terminal regions of the protein. 
However, we cannot rule out the involvement of other 
protein kinases for which we have not tested. 
Any of the previous protein kinases could be responsi- 
ble lbr the in vivo modification of tau in COS-I cells. 
Although co-transfection experiments using tau and GSK 3 
or MAP kinase cDNAs have demonstrated that tau protein 
is a substrate for GSK 3c~ and 13 (but not for MAP kinase) 
in living cells [31,61], the nature of the protein kinase 
activities phosphorylating tau protein in vivo still remains 
to be elucidated. 
Our results also indicate that both MAP kinase- and 
GSK 3-enriched fractions are at least partially sensitive to 
in vitro DRB treatment, hus suggesting that these kinases 
may be involved in tau phosphorylation within COS-I 
cells. Interestingly, MAP kinase in non-neural cells is 
believed to down regulate GSK 3 through phosphorylation 
[58,59]. Thus, depending on the metabolic state of the cell, 
one or other protein kinase may be active. 
MAP kinase activity in non-neural cells is higher in 
proliferating than non-proliferating cells [59], so that in 
transfected cells it should have a decreased activity. If this 
is the case, then probably GSK 3 is the protein kinase 
acting mainly on tau in transfected cells. This possibility is 
supported by the fact that many of the features of tau-kinase 
in COS-1 cells are shown by GSK 3, such as elec- 
trophoretic mobility shift or the modification of the C- 
terminal residues (at the SMI-31 epitope) [28]. In addition 
to this, we have recently shown that GSK 3 13 may 
phosphorylate tau protein in vitro at the tubulin binding 
domain, in residues which are important for binding to 
microtubules and also phosphorylated in PHF-tau [62]. 
Thus, GSK 3 should be considered as a possible candidate 
for AD-type tau phosphorylation i  COS-1 cells. 
On the other hand, although both MAP kinase and 
GSK3 can modify tau in an Alzheimer-like state, phospho- 
rylated and unmodified tau show similar capacities to bind 
microtubules. The probable action of the previous kinases 
could be complemented by others) kinase(s) in order to 
have features of Alzheimer-like phosphorylation. 
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